LONDON--(BUSINESS WIRE)--Jan. 8, 2018--
LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a
market-leading medical technology company, today announced Matthew J.
Dodds has joined the Company as Senior Vice President, Corporate
Development. In this role, Dodds is responsible for Business
Development, Investor Relations and Corporate Communications.
“Matt brings an outstanding perspective on the industry and
macroeconomic trends that will enhance our strategic growth plans,” said
Damien McDonald, LivaNova’s Chief Executive Officer. “I am pleased to
welcome Matt to the LivaNova team, and look forward to working together.”
Dodds comes to LivaNova with more than 25 years of medical device
experience, most recently serving as Vice President, Strategic Planning
at Johnson & Johnson (“J&J”) Medical Devices. At J&J, Dodds led the
strategic planning process for the Medical Devices business and worked
closely with the business development and investor relations teams.
Prior to joining J&J, Dodds spent more than 20 years as a medical device
equity analyst. He served as Americas Sector Head, Healthcare Research
at Citigroup, and served as senior analyst at SG Cowen and UBS Warburg.
“I believe in the great work LivaNova is doing for patients around the
world,” said Dodds. “I look forward to supporting and shaping the
Company’s strategic goals, while helping deliver long-term value to its
Dodds earned his Bachelor of Science degree in industrial management
from Carnegie Mellon University.
LivaNova PLC is a global medical technology company built on nearly five
decades of experience and a relentless commitment to improve the lives
of patients around the world. LivaNova’s advanced technologies and
breakthrough treatments provide meaningful solutions for the benefit of
patients, healthcare professionals and healthcare systems. Headquartered
in London and with a presence in more than 100 countries worldwide, the
company employs more than 4,500 employees. LivaNova operates as three
business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm
Management, with operating headquarters in Mirandola (Italy),
Houston (U.S.A.) and Clamart (France), respectively.
For more information, please visit www.livanova.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180108005639/en/
Source: LivaNova PLC
LivaNova PLC Investor Relations and Media
Karen King, +1
Vice President, Investor Relations & Corporate
Deanna Wilke, +1 281-727-2764
External Communications Manager